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Heart failure (HF)-related hospitalization is associated with signiﬁcant mortality and
morbidity and can be prevented by early intervention. Implantable sensors detect early
pathophysiological changes in HF, using an accelerometer, a paced electrogram, impedance
and pressure sensors in implanted intracardiac leads, or stand-alone devices. Such sensors
monitor daily activity, QT and ST intervals, pulmonary ﬂuid, and intracardiac pressures
at various points. Sensor data are available either by patient’s or physician’s regular
interrogation, or using remote patient monitoring. Different sensors have different levels
of sensitivity and speciﬁcity for HF detection, and they have the ability to antedate HF
exacerbation and thereby allow for the initiation of intervention to avert decompensation.
Clinical studies suggest that alone or in combination, such sensors have a greater beneﬁcial
impact than conventional therapy on acute HF outcome.
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Acute decompensated heart failure (ADHF) refers to a
clinical condition of worsening HF with dyspnea, often
with evidence of ﬂuid overload [1]. This is generally
triggered by 1 of the 4 main factors: atrial ﬁbrillation,
anemia, hypertension, and medication/dietary indiscre-
tion. About 5 million Americans suffer from HF [2]. In the
1991–1994 Connecticut Medicare beneﬁciaries review
[3], ADHF necessitating hospitalization was found to be
associated with an in-hospital mortality of 8%. Impor-
tantly, of the 17,448 survivors, 44% were readmitted once,
with 18% of these patients being admitted due to recur-
rent HF. Overall, 24% died within 6 months of the ﬁrst
clinical manifestation of ADHF, and 53% either died or
were readmitted during the study period. Thus, preven-
tion of ADHF can have signiﬁcant prognostic value for
the patient, in addition to reducing the cost of HF
management.
2. Limitations of symptoms, signs, and investigations
While dyspnea is the commonest presenting symptom
for hospitalization in ADHF, it occurs relatively late in
association with hemodynamic and ﬂuid status changes.
Adamson et al. [4] implanted a right ventricular (RV)
sensor to measure RV systolic and diastolic pressure
during HF exacerbation in 32 patients. At a mean of
472 days before admission, RV systolic pressure started
increasing in the case of 9/12 HF events. Overall, there
was an increase in the RV systolic pressure by 2574% and
in the heart rate, by 1172% during ADHF. These ﬁndings
suggested that pressure changes are the mechanisms
responsible for initiating HF exacerbation. Similarly, a
study using an implantable intrathoracic impedance sensor
to assess pulmonary ﬂuid revealed that ﬂuid overloading
occurs at 18.3710.1 days before dyspnea occurred [5].
Thus, dyspnea is a late event and does not allow time for
the clinician to start or for the patient to seek appropriate
intervention and thereby avert hospitalization.
The cardinal physical signs of congestive HF are as
follows: a third heart sound, pulmonary crackles, raised
jugular venous pressure, and pedal edema. However,
these signs have poor sensitivity in detecting HF. In a
study [6] of 50 patients with raised pulmonary arterial
wedge pressure (PAWP; Z22 mmHg), lung crackles were
identiﬁed in only 19% of the patients, while a raised
jugular venous pressure and peripheral edema were
present in 50% and 20% of patients, respectively. Whilea third heart sound was heard in most cases, it was also
detected in those with a low PAWP. The combination of
these signs has a sensitivity of 58% and speciﬁcity of 100%
for diagnosing congestive HF. However, physical exam-
ination of jugular pressure is reported to be both difﬁcult
and inaccurate [7].
In a recent study [8], 134 patients with ADHF were
compared with a case-matched group of non-hospitalized
patients. Body weight gain 1 week before hospitalization
was associated with an increased risk of hospitalization.
However, while daily body weight measurement is recom-
mended in most HF guidelines, body weight is a non-speciﬁc
parameter and may be inﬂuenced by the amount of intake
and several other factors.
Radiological evidence of ADHF tends to appear late.
HF management is reported to be facilitated by a brain
natriuretic peptide (BNP)-guided approach; in a study
on HF therapy guided by the levels of N-terminal BNP
(TIME-CHF) [9], 499 patients who were aged Z60 years
and had systolic HF were randomized. Titration to achieve
an N-terminal BNP level of r2 times the upper limit was
compared to conventional management without BNP
guidance. There was no difference in the survival rates
between BNP-guided therapy and conventional therapy
(41% versus 40%), and both groups had a similar degree of
improvement in the quality of life (QOL). However, the
secondary endpoint of HF-related hospitalization was
signiﬁcantly reduced (72% versus 62%), and the outcomes
were better in the 60- to 75-year-old patients than in
those aged Z75 years.3. Does ambulatory monitoring prevent HF
decompensation?
While vigilant monitoring of symptoms and signs (and
BNP levels) is useful, it does not guarantee the accurate
prediction of ADHF. On the other hand, frequent monitor-
ing of some of these signs and symptoms and the use of
external physiological (and implantable) data have been
tested. A meta-analysis of both cohort (2354 patients) and
randomized trials (6258 patients) [10], with 6–12 months
of follow-up revealed a signiﬁcantly lower rate of deaths
and hospitalizations in patients receiving BNP-guided
therapy than in those receiving conventional therapy.
The Cochrane Database Systematic Review [11] examined
25 studies and 5 abstracts and has suggested that telephonic
support and telemonitoring are effective in reducing all-
cause mortality, HF-related hospitalization, and treatment
Table 1
Monitoring for heart failure pathophysiology.
Electrical
remodeling
Examples
Atrium Rate, atrial ERP, atrial ﬁbrillation
Ventricle Rate, ventricular ERP, ventricular
tachyarrhythmias
Conduction Atrioventricular node conduction time and
capacity, intra- and inter-atrial conduction,
intra- and inter-ventricular conduction
Mechanical
remodeling
Examples
Atrium Size, function, structure
Ventricle Size, function, structure
Pressure changes End-diastolic pressure, pulmonary artery
pressure (and wedge pressure), venous
pressure, left atrial pressure
Neurohormonal changes Examples
Sympathovagal imbalance Heart rate variability
Renin–angiotensin–aldosterone system BNP
BNP¼B-type natriuretic peptide.
ERP¼effective refractory period.
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evidence-based prescription.
The Randomized Trial of Phone Intervention in Chronic
HF (DIAL) trial [12] randomized 1518 outpatients to
either nurse-led, telephone-based intervention or conven-
tional treatment. Weight, diet, and medication compli-
ance were monitored, and nurse specialists adjusted
the diuretics doses according to certain speciﬁed criteria.
Patients were instructed to call 3 times at a frequency
of once every 14 days and, thereafter, at a frequency
depending on the severity of HF. This protracted study
followed the patients for up to 3 years after trial comple-
tion. The primary endpoint (death or HF-related hospita-
lization) was lower in the intervention than in the
conventional arm, with the main beneﬁt being a reduction
in hospitalization (28.5% versus 35.1%, at 3 years). An
educational effect and adherent to the above 3 supervised
areas were considered the main reasons for improvement.
The Telemedical Interventional Monitoring in HF (TIM-HF)
trial [13] also randomized stable Class II or III HF patients
with a history of HF-related hospitalization during the last
2 years to either conventional care or remote data mon-
itoring (ECG, blood pressure, and body weight); the latter
involved the transference of the collected data via a
personal digital assistant to the monitoring center daily,
followed by physician-led response. Over a median follow-
up period of 26 months, there was no difference in the
frequency of HF-related hospitalization or death, nor in
the overall QOL score. However, physical functioning
improved. The study documented an 81% compliance in
Z70% daily transmission of data. The Telemonitoring in
Patients with HF (TELE-HF) trial [14] randomized 1653
patients who were recently admitted with ADHF. Daily
telephone-based interactive voice-response systems on
symptoms and weight were reviewed by the patients’
physicians. At the end of 180 days, there was no signiﬁcant
difference in the primary endpoint of death and HF-related
hospitalization between the telephone-based intervention
group and the conventional care group (52.3% versus 51.5%,
respectively). Again, this study shows only a 55.1% adher-
ence to interventional therapy at the end of 26 weeks
among the 85.6% of patients who made at least 1 call.
The different efﬁcacies of telemonitoring reported bet-
ween meta-analyses and prospective studies may be attri-
butable to the differences in the severity of HF in the patients
involved in the studies, the types of clinical variables
measured, and the interventions offered. Important draw-
backs of these studies are sub-optimal compliance of subjects
and lack of rapid therapeutic intervention. Furthermore,
these studies have mainly been limited to easily measurable
clinical variables that occur relatively late in the course of
ADHF. Many patients with left ventricular (LV) dysfunction
require implantable cardiac implantable electronic devices
(CIEDs), either for arrhythmia prevention or therapy (ICD) or
HF treatment (cardiac resynchronization therapy, [CRT] or
CRT device with deﬁbrillator [CRT-D]); this opens the possi-
bility of adding implantable sensors for HF monitoring in
these devices. The use of implantable sensors will allow
continuous monitoring of physiological parameters without
the intensive use of manpower. Furthermore, the ability of
these sensors to detect early physiological changes beforeADHF may open a window for averting HF-related hospita-
lization. They can also facilitate the evaluation of the hemo-
dynamics at different body positions and on an ambulatory
basis and may obviate the need for invasive monitoring
when the patient is admitted for HF therapy.
4. Monitoring of pathophysiological changes in HF
Three possible pathophysiological areas for HF mon-
itoring can be deﬁned: monitoring of electrical remodel-
ing, mechanical remodeling, and neurohormonal changes
occurring with HF (Table 1). Electrical remodeling in either
the atrium or ventricle will result in changes in the normal
automaticity, conduction properties, and refractory period
and predisposition to atrial ﬁbrillation (AF) and ventricular
tachyarrhythmias. The occurrence of arrhythmias is routi-
nely monitored and treated by CIED, both by pacing and
deﬁbrillation. The effective refractory period (ERP) can
be monitored by physician-activated electrical stimulation
through a programmer. Intra- and inter-chamber conduc-
tion timings in HF are important; progressive PR and QRS
duration prolongation occur with a worsening of HF [15].
A wide LBBB QRS complex is associated with ventricular
dyssynchrony and impairs LV function.
The initiating event of HF is most often systolic LV
dysfunction. This will affect the sizes of the right and left
ventricles, and their systolic and diastolic functions. Early
recognition of these changes by monitoring may allow
pharmacological or interventional approaches to reverse
the changes before clinical HF develops; this may be
possible in patients such as those already implanted with
a device, such as a pacemaker, which enables long-term
monitoring of HF.
However, the major immediate clinical consequence
of HF is ADHR, which arises because of ﬂuid overload
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and volume statuses of the lungs and appropriate therapy
can prevent ADHF.
Finally, many neurohormonal changes develop sec-
ondary to the compensating mechanisms of HF. While
not easily measurable directly, these changes may be
reﬂected through heart rate variability and electrical
repolarization, which can be assessed by parameters such
as the QT interval. This will be an interesting new area for
monitoring and therapy guidance.
5. Sensors for heart failure (Table 2)
Sensors for HF monitoring can be classiﬁed according
to the technical instrumentation. Table 2 summarizes the
sensors that have been used or proposed to monitor the
events of HF. The paced QRS enables the determination of
the QT duration. In addition, the QRS width, measured as
the ventricular depolarization gradient, has been pro-
posed as a sensitive marker of catecholamine [16]. These
sensors have long been used as surrogate markers of
sympathetic activity, which increases with exercise.
High percentage of biventricular pacing is necessary
to deliver effective CRT [17] and is a good marker of HF
decompensation. AF and ventricular tachyarrhythmias
can either be a consequence or trigger event of HF that
can easily be recognized and treated. Heart rate variability
(HRV) can be measured in patients not yet rendered
pacing-dependent, and this factor is a well-established
prognostic marker because it reﬂects the level of sym-
pathovagal imbalance [18]. Reduction of HRV antedates
HF events.
Piezoelectric crystals are used to monitor body motion.
Decreased body activity is an intuitive consequence of HF
exacerbation.
Impedance refers to low, stimulating alternating cur-
rents that are of non-cardiac origin and are injected and
recorded between pacing electrode pairs. When impe-
dance was applied between RV and LV leads, the lead
conﬁguration will encompass part of the left ventricle,
thereby enabling the measurement of the intraventricular
volume and contractility. When the impedance is appliedTable 2
Classiﬁcation of heart failure–monitoring sensors according to the
technical realization.
Sensors Parameters
Piezoelectric/accelerometer Activity level
Paced electrogram QT
ST level
Impedance Minute ventilation
Respiratory rate
Pulmonary ﬂuid
Left ventricular
Volume and function
Special leads Pulmonary arterial and
Wedge pressures
Right ventricular pressure
Left atrial pressure
Myocardial contractilitybetween an intracardiac lead and the CIED casing, respira-
tory parameters such as the respiratory rate and minute
ventilation can be monitored; these parameters are
affected by tachypnea occurring in ADHF. This electrode
conﬁguration can also detect pulmonary ﬂuid status,
serve as a marker of pulmonary edema, and monitor the
respiratory rate.
More direct measurements are now possible with
pressure sensors instrumented in the RV, pulmonary
artery (PA), or in the left atrium (LA). Since central
hemodynamic changes are the precipitating events of
ADHF, pressure sensors that measure LA, PA, and RV
pressures have been developed and investigated. Recent
developments and clinical applications of some of these
sensors are summarized below.
5.1. Activity monitoring
Kadhiresan et al. [19] reported the use of externally
attached accelerometers at the chest wall to monitor
walking distance in HF patients. Using an acceleration
threshold of 50 mG, a walking speed of 2 mph (approx-
imately¼2.8 METS) can be detected in a group of 30
patients. The activity log index so deﬁned was closely
related to the walking distance of these patients, and the
index was higher in the CRT-on phase than in the CRT-off
phase. Similarly, the number of times per day when physical
activity was greater than a threshold of 70 steps/min was
determined by an implanted accelerometer sensor [20], and
the trend of the activity level was similar to that of HRV
during ADHF and correlates with the NYHA class at baseline.
Although a crude index, activity is a good reﬂection of the
general well-being of a HF patient. It is a readily available
sensor in most CIEDs, and uses minimal battery energy. In
addition, the absence of activity usually signiﬁes the patient
is at rest and allows other measurements, such as respiratory
parameters, to be determined in the baseline state. An
activity sensor is used in conjunction with other sensors for
HF monitoring.
5.2. Heart rate variability
In patients with HF, neurohormonal activity predicts
the cardiovascular outcome. HRV is an indirect measure of
autonomic tone and predicts both sudden and non-sud-
den cardiac death [21,22]. HRV has been proposed to not
only prognosticate HF severity but also serve as a guide
for the treatment and prediction of ADHF.
In a randomized study of 50 patients with an
implanted CRT device [23], HRV was measured in the
atrial sensing mode (VDD at 30 bpm) in either the CRT-on
or CRT-off mode. HRV, measured as the SD of the atrial
cycle length of all atrial sensed beats, was signiﬁcantly
higher in the CRT-on than in the CRT-off arm (25% higher)
and in patients receiving a betablocker than in those not
receiving it (27% higher).
In the Boston Scientiﬁc device, HRV is measured by the
SDANN. SD of the intrinsic intervals in the 288 ﬁve-
minute segments of a day is measured and averaged over
a week. If the percentage of intrinsic beats is less than
67% for 24 h, the data for that day is discarded. Using the
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CRT resulted in a reduction in the ventricular heart rate and
mean heart rate and an increase in SDANN (from 69723ms
to 93727ms) after 3 months. Furthermore, lack of HRV
improvement predicts non-responders to CRT [24].
With the Boston Scientiﬁc CRT device, the HRV can be
plotted at each heart rate over a 24-h period, resulting in
the so-called ‘‘foot-print’’ [25]. The normalized size of the
foot-print is termed the foot-print number, and the graph
and number give an easy understanding of the level of
HRV: ‘‘the larger the better.’’ In another cohort study [26],
HRV using either the SDANN or foot-print was used to
predict mortality in 842 patients implanted with CRT
during a 11.8-month follow-up period.
In the CRT RENEWAL study, a 436-patient cohort was
evaluated for clinical scores derived on the basis of diag-
nostic data obtained 2 weeks after implantation. The
patients were assigned scores on the basis of the following
criteria: SDANN of o43 ms; mean heart rate, 474 bpm;
foot-print number, o29; and activity percent, o5% from
[27]. This scoring system was used to classify patients into
low-, moderate-, and high-risk groups. When applied to a
separate group of CRT recipients in the HF–HRV cohorts, this
scoring system accurately predicted the mortality risk (low,
2.8%; moderate, 10.1%; and high, 13.4%) on the basis of
tertiles of their scores.
In the Medtronic device, a long-termmeasure of HRV—
the SD of a 5-min median AS–AS interval (SDAAM)—is used.
The algorithm averages the 24-h SD of intrinsic atrial cycle
length and will exclude the day’s data if the percentage of
atrial pacing exceeds 80% or detects an atrial high-rate
episode (AHRE). The change in SDAAM is compared to a
rolling average of the preceding 6 months. The SDAAM,
night-time heart rate, and activity level were used to predict
outcome and HF-related hospitalization in a 397-patient
cohort [28] (Fig. 1). A SDAAM of o50ms predicts overallFig. 1. Performance for SDAAM, night heart rate, and patient activity to
detect ADHF. Plots show sensitivity to detect impending cardiovascular
hospitalization versus number of false-positive detections per patient-
year of monitoring, as a function of detection threshold. SDAAM¼stan-
dard deviation of median sensed atrial to atrial intervals.
Reproduced with permission [28].mortality, and the absolute value of SDAAM remains low in
those who were either hospitalized or died. SDAAM declined
from 76727ms to 64726ms at the time of hospitalization,
and the change was apparent up to 3 weeks before the event.
These data suggest that autonomic surveillance of para-
meters, such as the HRV, is a good method for both
monitoring HF prognosis and predicting ADHF. HRV has
limited value when the percentage of atrial pacing is high
and during atrial tachyarrhythmias; additionally, its mea-
surement is affected by medications.
5.3. Percent biventricular pacing
In a cohort retrospective analysis of 2 HF trials of CRT-
D (1812 patients), Koplan et al. [17] analyzed the relation-
ship between the percentage of biventricular pacing and
the outcomes of death and HF-related hospitalization. A
44% reduction was noted in the event rates in those paced
100% of the time versus those paced for less than 92%. The
main reason for an inadequate percentage of pacing was
atrial arrhythmia. Thus, a high percentage of biventricular
pacing of Z98% is an important goal to achieve in patients
with CRT.
In patients with AF, the 12-lead Holter System may be
needed to monitor ‘‘true’’ complete biventricular capture
using a template-matching system because of fusion
complexes [29].
5.4. Right ventricular pressure
PA pressure and PAWPmonitoring have been shown to
be effective for tailored therapy in patients admitted with
advanced HF [30]. Early attempts have been made to
continuously record PA pressure on an ambulatory basis
[31,32]. An implantable pressure sensor has been incor-
porated into a pacing electrode with a preliminary appli-
cation for rate-adaptive pacing [33]. This sensor is a
hermetically sealed piezoelectric crystal with a dia-
phragm facing the blood stream. Early experiences have
shown the continuous recording of RV pressure by con-
necting this electrode to an implanted hemodynamic
monitor [34,35].
The Medtronic Chronicle IHM (Model 9520) is a non-
pacing, implantable pulse generator capable of external
radiofrequency connection and integration in a web-
based system. Piezoelectric activity from a passively ﬁxed
lead in the RV outﬂow tract is sampled up to once every 2
s timed to the sensed unipolar RV electrogram. It has been
shown that PA diastolic pressure can be estimated at the
time of the maximum positive RV dp/dt [36]. Pre-implant
calibration pressure is required to facilitate absolute
pressure measurement.
5.4.1. Feasibility study
In one study [37], serial Swan-Ganz catheterizations at
3, 6, and 12 months after implant showed a small baseline
error of o1 mmHg 12 months after the implantation.
Furthermore, the accuracy of pressure measured is not
affected by body posture. Adamson et al. [4] studied 32 HF
patients who underwent implantation of Chronicle IHM.
They found that long-term RV pressure was stable in most
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RV systolic pressure increased by 2574%; heart rate, by
1172%; and estimated PA diastolic pressure, by 2674%.
Increases in one of the pressures occurred in 9/12 events
among patients who underwent HF-related hospitalization,
but in 9/24 events among non-hospitalized patients. During
a volume-depleted state in 7 patients, RV pressure para-
meters were reduced. All patients returned to baseline
levels after therapeutic intervention. A sustained increase
in one of the pressures (420% from baseline) occurred in
patients subsequently admitted, at a mean of 4.2 days
before admission. When the device data were available to
the monitoring physician, a reduction in HF-related hospi-
talization was subsequently observed. Zile et al. [38] com-
pared the ongoing RV hemodynamics between systolic and
diastolic HF patients during HF events. They found that RV
diastolic pressure was elevated in both conditions, although
there was a tendency for more rapid elevation of the
pressure in diastolic HF, with less compliable ventricles,
than during systolic HF. Thus, besides monitoring HF for
intervention, the implantable pressure device enables an
understanding of HF pathophysiology that was hitherto
impossible.5.4.2. Clinical outcome study
The Chronicle Offers Management to Patients with
Advanced Signs and Symptoms of HF (COMPASS-HF)
Study [39] prospectively randomized 274 NYHA Class III
or IV HF patients to receive conventional care or therapy
guided by Chronicle-derived RV pressure parameters.
During a follow-up of 6 months, there was a statistically
insigniﬁcant trend for reduction of either HF-related
hospitalization or the need for intravenous diuretics
(primary endpoint) by 21%. A post-hoc analysis showedFig. 2. Time to ﬁrst heart failure (HF) hospitalization in a post-hoc
analysis of class III/IV HF in COMPASS-HF Study. There was a 33%
improvement in the time to the ﬁrst HF events. Hazard ratios (HRs)
are from a Cox proportional hazards regression model. CHRONICLE¼
medtronic implanted hemodynamic monitor.
Reproduced with permission [39].a 36% prolongation in time to the ﬁnal HF-related hospi-
talization in the Chronicle-guided treatment group
(Fig. 2). A subgroup analysis [40] found a 20% insigniﬁcant
reduction in HF events when diastolic HF patients were
managed according to Chronicle-derived data. This will be
of interest in future larger trials to prevent HF in diastolic
HF, which has few proven therapies.
5.5. Other pressure sensors
5.5.1. Left atrial sensor
PA diastolic pressure is an indirect assessment of the
ﬁlling LV pressure, and an increase in LA pressure pre-
cedes pulmonary congestion. This may allow a longer
time window for physician intervention to avert ADHF.
The HeartPOD LA pressure monitoring device (St Jude
Medical Inc.) comprises an implantable sensor lead that is
attached to a coil antenna for telemetry of sensor signals
(Fig. 3). The sensor is a pressure sensor with a titanium
pressure sensing membrane of 37 mm2. It is capable of
measuring high-ﬁdelity pressure and temperature, and
electrogram recording. An external patient advisory mod-
ule (PAM) sends a 125 KHz radiofrequency transmission
to the antenna, which then captures 20-s sensor data. The
PAM has 13 MB of memory and can store about data
during data for 3 months, with 6 recordings per day.
In a single-center feasibility study [41], 8 patients
underwent implantation of the LA pressure device using
a transeptal approach from the femoral vein. All patients
received dual antiplatelet therapy for 6 months (aspirin,
160 mg and clopidogrel, 75 mg per day). The device was
calibrated over time using a Valsalva maneuver technique
during which the expiratory pressure, as measured by the
PAM, will equate to the LA pressure. Over a period of 6
months, the net drift was 0.271.9 mmHg per month,
although in 1 patient the drift was much more, probably
due to malalignment of the sensor to LA walls.
The Hemodynamically Guided Home Self-Therapy in
Severe HF Patient (HOMEOSTASIS) trial enrolled 40
patients with Class III to IV HF [42]. All patients under-
went implantation of a LA pressure device, although
sensor failure occurred in 4 patients. After a 3-month
run-in period during which HF-related hospitalization,
related events, and medication dosages were documen-
ted. Thereafter, LA pressure data were disclosed to the
patients, who in conjunction with the physician, adjusted
the diuretic dosages. Survival without HF events occurred
in 61% at 3 years. Mean daily LA pressure therapy resulted
in a fall of LA pressure (17.6 mmHg to 14.8 mmHg),
reduction in elevated LA pressure frequency (events
425 mmHg by 67%), and better NYHA Class, LVEF, and
more frequent up-titration of angiotensin-converting
enzyme inhibitors and reduction in diuretic dosages.
The HOMEOSTASIS trial is an interesting observational
study in which the LA pressure parameter is treated
similar to blood glucose parameters in a diabetic patient,
and self adjustment of dosages of diuretics helped main-
tain a euvolemic state. Thus, the possibility of reduced
clinical events may be due to the up-titration of angio-
tensin-converting enzyme inhibition by reducing the dose
of diuretics, if LA pressure is low. Conversely, when LA
Fig. 3. The HeartPOD left atrial pressure sensor. (A) Patient advisory module. (B) Left atrial pressure sensing device. (C) Close-up image of the sensor tip.
Reproduced with permission [41].
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enable the administration of a larger dose of betablockers.
As a result, the target doses of both drugs were achieved
in 54% of patients as against only 27%, at baseline.
The LA pressure sensor is an interesting device that
requires further study in prospective randomized trials. At
present, there remain issues of sensor stability, ease of
implant (subclavian implant tools are now available), and
the risk of thromboembolism.
5.5.2. Pulmonary arterial pressure sensors
Diastolic PA pressure is a surrogate measure of PAWP.
An implantable wireless PA pressure transducer (W-IHM)
has been developed (Cardio-MENS, Atlanta, GA, USA) [43];
this device is capable of transmitting continuous PA
pressure readings when powered by radiofrequency sig-
nals from the outside (Fig. 4A). The recordings of this
device have been shown to correlate with direct PA
pressure measured invasively and with echocardiographic
Doppler data [44]. The cardioMENS Heart Sensor Allows
Monitoring of Pressure to Improve Outcomes in NYHA
Class III HF Patients (CHAMPION) [45,46] trial investi-
gated the use of such a sensor in 550 patients in the US. In
this trial, 280 patients were randomized to be blinded to
the sensor information and receive conventional treat-
ment and 270 patients, in the active group in which PA
pressure was measured daily by W-IHM; the latter group
showed a signiﬁcant (39%) reduction of HF-related hospi-
talization (Fig. 4B). The secondary endpoints of mortality,
QOL, and duration of HF-related hospitalization were
also improved. There was no device failure, and system-
related complications only occurred in 8 patients, with 1%
implant-related complications. All patients were either
continued on warfarin or aspirin after 1 month of dual
anti-platelet therapy. No episode of pulmonary infarction
or embolism related to the sensor was reported.
The CHAMPION study is the ﬁrst large study to conﬁrm
the role of implantable pressure sensor data to reduce
HF morbidity. Unlike telemonitoring that involves only
clinical and non-invasive HF parameters, the invasively
derived PA pressure measurement allows the physician toadjust neurohormonal, diuretic, or vasodilator drugs, with
an aim to reduce PA pressure. There were more changes in
medications, and the beneﬁts were observed both in the
systolic and non-systolic HF groups. Other implanted PA
pressure devices are also under development. For example,
an external ultrasound-activated PA pressure sensor
(InPressure, Remon Medical Technologies, Boston Scienti-
ﬁc) which is ﬁxed in the right PA and has a self-expanding
wire mesh, has been tested in 31 patients with chronic HF
(PAPIRUS study). Its pressure recordings are reported to be
similar to data obtained by the Millar catheter [47].5.6. Intrathoracic impedance for pulmonary ﬂuid status
Dyspnea is the commonest presenting symptom for
ADHF, and congestion or edema are the main underlying
mechanisms for dyspnea. Increase in ﬂuid in the lungs
will decrease the transthoracic impedance, which can
now be measured with an implantable device.5.6.1. Device description
The concept of impedance to monitor pulmonary con-
gestion is based on a canine experiment by Wang et al. [48].
The Medtronic OptiVolTM ﬂuid management system uses
transthoracic impedance to measure pulmonary ﬂuid
(Fig. 5). Low-voltage, non-stimulating currents are injected
between the RV ICD electrode (e.g., InSyn Sentry) or RV
bipolar electrode (e.g., Advisa) to the ICD or pacemaker
casing between noon and 5 pm, at a time when the subject
is presumably ambulant and upright. A sampling once every
20 s is made and the average obtained. The moving average
of the impedance is used to establish a baseline impedance
level against which any change can be compared. The
algorithm is inactive for the ﬁrst 34 days after device
implantation to allow time for post-implant pocket healing
and electrode stabilization. When pulmonary ﬂuid has
accumulated beyond a programmable threshold, an alarm
is used to alert the patient (or the physician via remote
monitoring).
Fig. 5. Intrathoracic impedance measurement by an implantable system.
Reproduced with permission [5].
Fig. 4. Wireless implantable pulmonary artery (PA) pressure sensor.
(A) CardioMENS sensor for implanting in a distal branch of the PA.
(B) Cumulative heart-failure-related hospitalizations during entire per-
iod of randomized single-blind follow-up.
Reproduced with permission [46].
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The feasibility of using intrathoracic impedance to
monitor ﬂuid status has been tested in 34 patients with
NYHA Class III or IV HF in the MID-Heft Study [5]. A
deﬁbrillation lead in the RV apex is connected to a special
pacemaker capable of injecting and sourcing impedance.
The electrode pairs that connect the RV coil to the device
case afford the best impedance signals.
During a follow-up of 2078.4 months, 25 adjudicated
HF-related hospitalization events were recorded for 10
patients. Intrathoracic impedance started to decrease before
worsening symptoms at 15.3710.6 days, whereas dyspnea
was only reported during the 3 days before hospitalization.
For 17 hospitalization events, pulmonary capillary wedge
pressure was found to be signiﬁcantly correlated with
impedance (r¼0.61, po0.001), and impedance increased
as ﬂuid removal occurred with dieresis.
An algorithm for HF detection was derived from 6.2
patient-years of monitoring of 10 patients, and tested in
the remaining cohort (Fig. 6). A 60 O day was suggested
to have a sensitivity of 76.9% at the expense of 1.5false-positives per patient-year of monitoring. Early warn-
ing occurred at 13.476.2 days of HF-related hospitaliza-
tion events. This landmark study shows that intrathoracic
impedance is correlated with pulmonary congestion and
changes in a predictable manner as diuresis occurs, thereby
facilitating acute monitoring. Furthermore, impedance
changes days before ADHF and suggests its role in mon-
itoring HF on an ambulatory basis.
5.6.3. Clinical outcome studies
The Italian OptiVol Study [49] on 532 HF patients
reported a 67% detection rate of HF necessitating hospita-
lization or therapy adjustment. In the remaining patients in
whom OptiVol alert was inactivated, HF-related hospitaliza-
tion was signiﬁcantly higher (20% versus 7%). The study also
showed a false-positive detection rate of 0.5 per patient-
year of follow-up.
Maines et al. [50] showed that a 12-week maturation
period was required for the pocket and the leads in the
de-novo implants, but substantially shorter adaptation
period was required for the replacement group, suggest-
ing that the adaptation is partly due to the leads or the
algorithm itself. Interestingly, using the RV–LV impedance
vectors, they showed that the impedance measured in the
responders and non-responders were signiﬁcantly differ-
ent, with the biventricularly measured impedance being
higher in the responders. This suggests that impedance
may play a role in tracking responders to CRT.
In a multi-center study of 558 HF patients implanted with
In Sync Sentry from 34 Italian centers, the device-recorded
OptiVol ﬂuid index of above 60O day was associated with
a 36% increased risk of HF-related hospitalization over
3267216 days of follow-up [51]. Multivariate analysis
showed that in addition to the OptiVol ﬂuid index, a higher
percentage of days with low activity, low HRV, and increased
Fig. 6. (A) Operation of algorithm for detecting decreases in impedance
over time. Differences between measured impedance (bottom) and
reference impedance (solid line) are accumulated over time to produce
ﬂuid index (top). Threshold is then applied to ﬂuid index to detect
sustained decreases in impedance. (B) Example of impedance reduction
before heart failure hospitalization (arrow) for ﬂuid overload and
impedance increase during intensive diuresis during hospitalization.
Label indicates reference baseline (initial reference impedance value
when daily impedance value consistently falls below reference impe-
dance line before admission). Magnitude and duration of impedance
reduction are also shown. Days in hospital are shaded.
Reproduced with permission [5].
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talization. In 62 patients for whom the OptiVol algorithmwas
used, prospective observational measurements of NT-pro-
BNP, i.e., clinical HF statuses, were obtained over 2772
weeks [52]. There was a signiﬁcant but weak relationship
in all pooled change in impedance and change in NT-Pro-BNP
levels over all the visits (r¼0.30, po0.001). However, the
NT-pro-BNP level increased signiﬁcantly when an OptiVol
alert was associated with clinical signs of ADHF (89725%
increase), whereas an insigniﬁcant increase was noted in the
absence of such signs (25% increase). In patients receiving
an alert, NT-Pro-BNP increased by more than 10% in most
incidents. By the time of the patient’s medical visit, impe-
dance continued to fall, indicating a worsening HF status.
In 42% of the cases, a device alert was not related to clinical
signs of HF, although overall BNP increased signiﬁcantly
by 25% in these patients. This could be attributed to an
improvement of medication/dietary compliance by the
patients due to the alert, the lesser sensitivity of signs of HF
than objective monitoring, or true false detection by OptiVol.
The usefulness of OptiVol in preventing HF was
reported in a single center, case–control study in which
27 patients implanted with InSyn Sentry was compared
to a clinically similar group of 27 patients with CRT-D
without OptiVol [53]. In the former group, 12/27 patientshad OptiVol alerts, resulting in intervention; and hospi-
talization occurred in only 1/27 over a year of follow-up.
In contrast, 7/27 patients had HF-related hospitalization
in the controlled patients treated with conventional
CRT-D without the OptiVol algorithm. When coupled with
remote patient monitoring (Medtronic Carelink), 20/28
(71%) OptiVol alerts in 67 patients could be remotely
managed [54]. A temporal relationship has been reported
between arrhythmias and OptiVol-measured ﬂuid level.
In a study [55], OptiVol threshold crossing 460 Oday was
related to a high risk of occurrence of AF. AF occurred
in 43% before or 29% after OptiVol level crossing. This
relationship was not veriﬁed in another study [56]. How-
ever, the latter study showed a higher prevalence of VT/VF
at lower level of OptiVol 15–45 O day, suggesting that
VT/VF occurred at the time of ﬂuid index crossing. The
ability of the ﬂuid index to predict the occurrence of
arrhythmia requires further study.
5.6.4. Algorithm considerations
Small et al. [57] investigated a cohort of 326 patients
implanted with InSyn Sentry, who were followed up for
almost a year. In the ﬁrst 4 months (observational period),
threshold crossing at the nominal 60 O day occurred in
17 patients (22 ADHF episodes). The occurrence of thresh-
old crossing predicted a 35% increase in hospitalization
during the subsequent period. Furthermore, the following
criteria are predictive of hospitalization: more than 3
threshold crossings per year or more than 30 days of
threshold crossing per year. When a multivariate analysis
was applied, only night-time heart rate remained pre-
dictive of ADHF in addition to the crossing of the OptiVol
threshold. Thus, both the crossing of the threshold and the
duration for which OptiVol level exceeds the programmed
threshold are predictive of HF-related hospitalization.
The threshold for OptiVol alert has also been tested in
115 patients implanted with Medtronic InSyn Sentry CRT-D
[58]. During a follow-up of 975 months, 45 OptiVol alerts
occurred in 30 patients; 15 of these alerts (33%) were
correlated with clinical signs and symptoms of HF, and the
authors suggested that the threshold be increased to
90O day to increase the speciﬁcity to 73%. The authors
did not ﬁnd any causes for false-positive alerts, but patients
with HF had signiﬁcantly higher OptiVol level versus those
without. On the other hand, in the European InSyn Sentry
Observational Study on 373 subjects [59], the level of
60O day was associated with a 60% sensitivity and 60%
positive prediction of ADHF. This study documented that
9/53 (17%) events were not associated with an OptiVol alert,
and in an additional 11 events, an increase in the OptiVol
level occurred but did not exceed the programmed detec-
tion threshold. These studies conﬁrm the usefulness of
intrathoracic impedance in monitoring ADHF, but pointed
out the need for ﬁne tuning the detection algorithm and/or
individual programming of the OptiVol detection level.
The SENSE-HF study is a prospective trial to assess the
sensitivity and positive predictive value of implantable
intrathoracic impedance to predict HF-related hospitali-
zation [60]. The study comprises 3 phases and has
completed recruitment in 2008. Phase I is a double-blind
phase that focuses on retrospective analysis of the value
Table 3
Changes in intrathoracic impedance due to reasons other than pulmon-
ary congestion.
Mechanism Examples
Blood viscosity Anemia
Extrapulmonary changes Pleural effusion, pneumothorax
Right-sided heart failure Peripheral edema not detected
Pulmonary changes Pneumonia
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which takes place 6 months after Phase I, the device alarm
is used to identify ADHF. When this happens, the patients
enter Phase III in which the utilization of OptiVol level is
assessed prospectively in averting ADHF and its implica-
tion on hospital resource utilization.
5.6.5. Advantages and limitations
The advantages of the intrathoracic impedance sensor
is the relative ease of instrumentation, which eliminates
the need for additional leads or complexity of implanta-
tion. The battery energy expenditure is low. It has been
relatively well-characterized in acute settings and for
long-term monitoring. While it has a high sensitivity, its
speciﬁcity may be limited as impedance in the vector
used may be liable to alteration by a number of clinical
events that do not indicate pulmonary congestion, such as
the occurrence of pleural effusion or pneumothorax [61]
(Table 3). However, some of the OptiVol alerts without
clinical evidence of HF might represent spontaneous HF
improvement due to delayed presentation, i.e., subclinical
congestion, in addition to being false positive. Never-
theless, when combined with other sensors, intrathoracic
impedance is useful for long-term and acute monitoring
of HF (see below).
5.7. Intracardiac impedance
Impedance signals derived from fully intracardiac
electrodes reﬂect volume changes of the heart more
closely than transthoracic impedance. Indeed, Salo et al.
[62] reported the use of a tripolar RV lead to measure RV
volume changes during the cardiac cycle, from which RV
volume and contractility can be derived for rate-adaptive
pacing. With the addition of a LV lead in CRT, more
accurate measurement of LV volume is now possible for
HF monitoring.
5.7.1. Unipolar impedance from the right ventricle
Unipolar impedance applied from the RV apex to the
CIED casing samples a small region in the cardiac apex.
This results in a signal that has been termed closed-loop
stimulation (CLS) sensor. Since the majority of the current
is dissipated over a distance of about 1 cm from the apex,
the signal reﬂects the regional contractility of the ven-
tricle rather than a change in stroke volume. While useful
for rate-adaptive pacing, unipolar impedance reﬂects LV
contractility only when the changes are sufﬁciently gross
and may not be able to detect small changes in cardiac
contractility, which is required in HF monitoring.5.7.2. Multipolar impedance
Several groups and manufacturers have conducted inves-
tigations on the optimal electrode arrangement for detecting
ventricular volumes. With currents ﬂowing between intra-
cardiac electrodes (RV, LV, and RA) and to the CIED casing,
enlargement in ventricular volumes will decrease the impe-
dance since more of the heart is encompassed by these
impedance vectors. Four intrathoracic and 2 intracardiac
vectors were examined in 16 dogs and 5 sheep [63].
Impedance values measured by all vectors decreased with
the onset of HF, with the maximum decrease occurring with
LV-Can and LV–RV. Importantly, HF-related changes are
greater for LV-Can impedance than vectors involving the
right heart electrodes (RA-Can, RV-Can, and RV Coil-Can),
while those for RV–LV and LV–RA are intermediate. LA
pressure showed greater correlation with LV-Can impedance
(r2¼0.73) than RV-Can (r2¼0.43) and RV Coil-Can (r2¼0.52)
impedance. Circadian variation in impedance also decreased
in HF (572% to 271%). Thus, in these animal models, the
incorporation of a LV vector signiﬁcantly improves the
detection of LV volume increase occurring in HF.
Biventricular impedance has been measured using a
quadripolar electrode arrangement [64,65]. In 9 mini-pigs
with pacing-induced HF, biphasic pulses (15 ms, pulse
width; 600 mA, constant current amplitude) were applied
between the RV ring and tip electrode, and impedance
was sourced using the LV ring and tip electrode. ‘‘Stroke
impedance’’ was calculated as the difference between
impedance values during systole and diastole. Systolic
impedance was deﬁned as the highest impedance
50–500 ms after the R-wave, whereas diastolic impedance
was measured during a 20-ms window within the
R-wave. After 20 days of HF induction by rapid pacing in
these animals, the increase in LV end-diastolic pressure was
found to be signiﬁcantly correlated with the end-diastolic
impedance, which decreased by 30% (r¼0.81, po0.001).
End-diastolic volume also trended in the same direction as
the impedance value, which decreased by 20%. The corre-
sponding intrathoracic impedance decreased by 8%, which
had a poorer correlation with the end-diastolic pressure.
These animal experiments suggest that biventricular
impedance can be used to monitor LV size and pressure
changes that occur with HF. Theoretically, the advantages of
using biventricular impedance over transthoracic impedance
are that there will not be signiﬁcant time lag for lead/pocket
maturation and the measurement will not be affected by
pulmonary conditions, such as pleural effusion and pneumo-
nia. Because the elevation of LV end-diastolic pressure occurs
earlier than pulmonary edema, this sensor can be used to
detect deterioration of early HF, where signiﬁcant pulmonary
ﬂuid accumulation has not occurred and for monitoring LV
function. The limitations include the need of a LV lead (which
restricts its use in a CRT device), dependence on the relative
position of RV–LV leads (only relative changes rather than
absolute value can be detected), and signiﬁcant diurnal (and
possible postural) changes that need to be accounted for in
an implantable system.
5.7.3. Clinical studies
An acute study was conducted on biventricularly
measured impedance in 14 HF patients during implantation
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different LV lead locations on biventricular impedance
measurements, and changes in stroke volume were induced
with overdrive pacing. Pooled data obtained from a study of
20 overdrive pacing episodes and 6 different lead locations
showed good correlation between stroke impedance mea-
sured with stroke volume (r¼0.8270.10) and pulse pres-
sure (r¼0.8170.16). The authors reported no signiﬁcant
effect of LV lead positions, but the accuracy and signal sizes
tend to be better in the mid-ventricular region than in the
basal and apical regions (Fig. 7).
Currently, data on long-term implants is scarce. The
relative merits and limitations of intrathoracic and intra-
cardiac impedance are summarized in Table 4. In patients
with a suitable device (i.e., with an LV lead), it is very
likely that a combined transthoracic and biventricular
impedance can be used.
5.7.4. Minute ventilation and respiration rate
Dual sensor pacemakers that encompass activity and
minute ventilation (MV) have been developed for rate-
adaptive pacing. HF leads to compensatory hyperventila-
tion, especially in the resting state. An algorithm [67]
published that includes mean daily resting and MV duringFig. 7. Biventricular impedance derived raw data recording (ECG, surface elect
Vertical lines 100 ms in front of the QRS complex). The respiratory inﬂuence is
Reproduced with permission [66].
Table 4
Intrathoracic versus intracardiac impedance.
Intrathoracic impedance
Heart failure parameters Pulmonary edema
Electrode arrangement RV lead or coil to casing (t
Lead/casing maturation Takes up to 1 month
Inﬂuence of lung disease Yes
Inﬂuence of lead location Less
Circadian & postural effect Yes
Sensitivity & speciﬁcity 70% (depends on thresho
Applicability Pacemakers and ICD
Clinical evaluations Relatively extensiveactivity and mean daily activity level. A stable MV and
activity level will suggest stable clinical HF, whereas an
increase in MV, especially at rest and combined with a
decrease in activity, suggests deterioration of HF. Con-
versely, a stable MV level with an increase in activity
indicates recovery from HF. Nineteen patients who had
no history of HF and underwent TalentTM (Sorin-ELA,
Italy) implantation were compared with 48 HF patients
implanted with Talent CRT. Wide inter- and intraindivi-
dual variability was noted, and fast Fourier transformed
data allowed for 7-day periodicity. While mean activity
was similar in the 2 groups, the resting and activity
MV levels were higher in the CRT group. Overall, it was
reported that the algorithm has a sensitivity of 88%,
speciﬁcity of 94.7%, positive predictive value of 71%, and
negative predictive value of 98.2% for HF.
Unlike MV, which can only be measured in relative terms,
respiratory rate can be easily assessed. It is anticipated
that respiratory rate will increase during ADHF, although
investigations regarding this aspect are minimal. The Boston
Scientiﬁc has introduced an ICD (EnergenTM) capable of
monitoring the respiratory rate. Further investigation, espe-
cially in relation to interference and accuracy in prediction of
ADHF, will be required to verify its effectiveness.rocardiogram; AortaP, aortic blood pressure; Z, intracardiac impedance.
clearly visible in the pressure and impedance traces.
Intracardiac biventricular impedance
LV volume and contractivity
ripolar) RV–LV bipoles (quadripolar)
Less
Less
Signiﬁcant
Yes
ld) N/A
CRT-P or CRT-D
Limited
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ST segment deviation heralds either ischemia or myo-
cardial injury. Myocardial ischemia requires medical
therapy or revascularization, especially in symptomatic
individuals. Myocardial injury, on the other hand, is a
medical emergency that calls for emergency reperfusion.
Prompt treatment of myocardial infarction will signiﬁ-
cantly reduce mortality. Delay in the recognition of chest
pain due to infarction (and in some instances, silent
infarction) is a signiﬁcant contribution to the appearance
of the delayed presentation of myocardial infarction.
Since long-term external ambulatory ECG recording may
not be practical, intracardiac electrograms have been
tested and thought to reﬂect infarction and ischemia in
an animal model [68]. When incorporated into a CIED
with patient alert and remote monitoring, ST segment
monitoring becomes a possibility.
The Angel Med Guardian (now under St Jude Medical)
is a single-chamber device with an RV apical lead. An
intracardiac electrogram (ICEG) was derived from the RV
apex to the device casing. The device records a 10-s ICEG
once every 90 s for normal sinus beat within 50–90 bpm.
Data are ampliﬁed with a gain of 62.5–625 times and
band passed between 0.25 to 45 Hz, followed by A/D
conversion at 200 Hz. ST segment level is compared to the
corresponding PQ segment level, and a baseline ST seg-
ment level is calculated as a rolling 24-h average, which
is determined hourly. The extent of the deviation is
normalized by the average R wave voltage, including the
effect of heart rate tested during an exercise. A rate-
adjusted spontaneous ST deviation can then be consid-
ered as an ischemic event, and an alert will be triggered.
A limited number of devices have been implanted in
humans [69]. During angioplasty with temporary coron-
ary artery occlusions, ST segment deviations occur, with
a negative shift in the presence of occlusion of the left
anterior descending artery and a positive shift in that of
other arteries. In this study, 10 abnormal alerts occurred
in 6 patients, necessitating coronary artery interventions.
In addition to its usefulness in the detection of ische-
mia, ST deviation may shed light on the ischemic cause
of arrhythmia, by virtue of its association with the occur-
rence of arrhythmias, such as ventricular tachycardia. Apart
from its logistic implications, ST segment monitoring (whichTable 5
Cardiac compass heart failure device diagnostic parameters and algorithms.
HF device diagnostic parameter Algorithm
AF duration AF for Z6 h on at least 1 day in
Ventricular rate during AF AF for 24 h and the average ven
Fluid index (OptiVol) High ﬂuid index on at least 1 d
Patient activity Average patient activity o1 h o
Night heart rate Average night heart rate of 48
HRV HRV of o60 ms everyday for 1
Percent of pacing CRT Ventricular pacing r90% for 5
ICD shock for potentially lethal VT/VF Z1 Shocks during the evaluatio
AF¼atrial ﬁbrillation; AT/AF¼atrial tachycardia/atrial ﬁbrillation; CRT¼cardiac r
ICD¼ implantable cardioverter-deﬁbrillator; VT/VF¼ventricular tachycardia/ventrsometimes may require urgent intervention) will be possi-
ble only for patients not dependent on pacemakers. The
inﬂuence of medications, electrolytes, and heart rate on ST
segment needs further evaluation.
5.9. Peak endocardial acceleration
Peak endocardial acceleration (PEA) sensor has been
used for rate adaptation. The PEA signal measures the
closure sound of the mitral valve and reﬂects cardiac
contractility. A minimal PEA signal occurs during the
optimal AV interval in DDD devices [70] and reﬂects the
optimal AV interval in most patients. A new CRT-P (The
New LivingTM CHF, Sorin-Ela, Italy) is now available to
monitor heart function and program the AV interval in the
CRT device. The PEA is contributed by both the contrac-
tility and LV ﬁlling, and an index known as the PEA area
is derived by measuring the PEA values at different AV
interval scanning at each VV interval. The maximum PEA
area will deﬁne the optimal VV and AV interval for the
patient.
In 15 patients implanted with a CRT device with PEA
sensor, cardiac catheterization was performed and the LV
dp/dt and the PEA area were determined [71]. AV interval
was scanned between 60 and 220 ms. The authors noted
response to CRT (deﬁned by 10% increase in dp/dt) in 75%
of the patients. Concordance of PEA area versus the dp/dt
methods was noted in 8/12 patients. These data are
interesting, although the role of AV interval programming
over a long period is uncertain, and the ability of the
sensor to monitor LV function remains to be tested.
6. Combined heart failure diagnostics
The Program to Access and Review Trending Informa-
tion and Evaluate Correlation to Symptoms in Patients
with HF (PARTNERS HF) is an observational study on the
use of diagnostics to predict HF [72]. Hundred sites in the
US prospectively recruited 694 patients implanted with
CRT-D and followed them for 11.772 months. Table 5
shows the diagnostic data considered important in an
algorithm to predict ADHF.
Ninety patients had 141 adjudicated HF events, occur-
ring after 60 days of implantation. A positive combined
diagnostic set predicts a 5.5-fold risk of hospitalization inpatients without persistent AF (7 consecutive days with Z23 h AF)
tricular rate during AF being Z90 beats/min on at least 1 day
ay; thresholds included, Z60, Z80, and Z100
ver 1 week (nonoverlapping weekly windows)
5 beats/min for 7 consecutive days (nonoverlapping weekly windows)
week (minimum 5 measured days; nonoverlapping weekly windows)
of 7 days (nonoverlapping weekly windows)
n period
esynchronization therapy; HF¼heart failure; HRV¼heart rate variability;
icular ﬁbrillation.
Fig. 8. Combined HF device diagnostics triggered. The Venn diagram shows that 72% of evaluations had Z2 HF device diagnostics triggered, with the
remaining 28% triggered by OptiVol Fluid Index Z100. OptiVol Fluid Index, low activity, and low heart rate variability (HRV) were the most common
reasons for triggers. HF¼heart failure; AF¼atrial ﬁbrillation; ICD¼ implantable cardioverter-deﬁbrillator; RVR¼rapid ventricular response.
Reproduced with permission [72].
C.-P. Lau et al. / Journal of Arrhythmia 28 (2012) 4–1816the next month, even after adjusting for the clinical
variables. The main diagnostic parameters are OptiVol
Z 60O. day, low activity, and HRV. When additional
OptiVol was Z100 (28% of patients), it was also predic-
tive of ADHF (Fig. 8). Further sub-group analysis sug-
gested that the speciﬁcity of ADHF is improved with
setting a higher level of ﬂuid index, and using more
non-ﬂuid related indices (at the expense of some loss of
speciﬁcity.) There is an improvement in the diagnostic
accuracy if sampling is performed every 15 days versus
less frequently. Further tests are required to verify
whether closer monitoring, such as with the use of remote
web-based system, can further reduce ADHF.
The PARTNERS HF is an important study that high-
lights the role of combined HF diagnostics in predicting
ADHF. While the sensitivity and speciﬁcity of the algo-
rithm needs to be tested in prospective randomized trials,
the occurrence of positive diagnostic criteria are predic-
tive of a group of high-risk HF patients. Conversely, the
absence of diagnostic alerts predicts a stable HF. This risk
stratiﬁcation is over and above that achieved with the
conventional clinical risk factors.7. Conclusion
Sensors have been introduced to optimize the pacing
rate in patients with chronotropic incompetence. With the
increasing use of devices to treat and monitor HF, sensors
have now metamorphosed from their role in optimizing HF
management to preventing the worsening of HF.Conﬂict of interest
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